Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
M C Keefer, M Wolff, G J Gorse...
https://pubmed.ncbi.nlm.nih.gov/9310283/Completed
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04
25
Participants Needed
3
Research Sites
N/A
Total Duration
To determine the safety of and immune response to vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) at a dose of 200 mcg in human volunteers; to evaluate duration of antibody response and its relationship to the dose and frequency of inoculation. Although recent advances have been made in antiviral therapy against AIDS, there is currently no cure for AIDS. It is likely that the ultimate control of the disease depends on the development of safe and effective vaccines against HIV.
CONDITIONS
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Immuno-US
Collaborating Sponsor
Inclusion Criteria
Patients must be:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded:
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
N/A
Model
N/A
Primary Purpose
PREVENTION
Number of Arms
0
M C Keefer, M Wolff, G J Gorse...
https://pubmed.ncbi.nlm.nih.gov/9310283/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Immuno-US
Collaborating Sponsor